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mouse epidermis does not provide the
microenvironment necessary for V600EB-
raf-driven melanomagenesis.
There are several plausible expla-
nations as to why epidermal mela-
noma developed in the Tyr-Q61KNras::
p19Arf/::K14-Kitl, but not in the
V600EBraf::K14-Kitl or mGluR1::K14-Kitl
mice. UV light is critical for efficient
melanomagenesis in Tyr-Q61KNras::
p19Arf/ mice (Ferguson et al., 2010)
and has been shown to recruit melano-
cytes to the epidermis of neonatal
mice (Walker et al., 2009). Perhaps
the exogenous KITL traps these newly
recruited melanocytes and simply in-
creases the chance that epidermal
melanoma will develop, or perhaps it
provides a microenvironment that sup-
ports melanomagenesis in this popula-
tion in this location. Alternatively,
differences in the timing of oncogene
expression (prenatal in Tyr-Q61KNras::
p19Arf/ mice, induced in juveniles in
V600EBraf::K14-Kitl and mGluR1::
K14-Kitl mice), whether p19Arf is de-
leted or not, or the genetic background
of the mice (pure C57BL6 compared
with mixed FVB/C57BL6) could ac-
count for the differences. Clearly, these
are testable hypotheses and, although
the KITL did not translocate V600EBraf
melanoma to the epidermis, it in-
creased tumor penetrance and reduced
tumor latency and does therefore pro-
vide a considerably more robust and
versatile mouse model of melanoma.
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TO THE EDITOR
Two major phenotypes of genetic in-
stability characterize cancer cells.
Although the majority of cancers are
hallmarked by large chromosomal al-
terations and aneuploidy, some cancers
are diploid or near diploid, but show
insertion/deletion mutations at repeti-
tive sequences, termed as microsatel-
lites (de la Chapelle, 2003).
The pathogenetic mechanism asso-
ciated with microsatellite instability at
multiple microsatellite loci in cancer
(high-level microsatellite instability,
MSI-H) is deficient of the DNA mis-
match repair (MMR) system (de la
Chapelle, 2003). Functional MMR
assures correct replication of DNA
sequences and is essentially rele-
vant for the correction of mismatches
resulting from polymerase slippage at
Abbreviations: BCC, basal cell carcinoma; MMR, mismatch repair; MSI-H, high-level microsatellite
instability; NMSC, non-melanoma skin cancer; SCC, squamous cell carcinoma
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microsatellites. As mononucleotide re-
peats inherently have a high degree of
instability, MMR-deficient cells particu-
larly accumulate insertion and deletion
mutations at mononucleotide repeats.
Microsatellite instability at mono-
nucleotide repeats is therefore the most
specific and sensitive indicator recom-
mended as a gold standard for the
detection of MMR deficiency-related
MSI-H (Umar et al., 2004).
The MSI-H phenotype in tumors,
mainly of the colorectum, is associated
with a distinct clinical behavior (Popat
et al., 2005).
Non-melanoma skin cancer (NMSC)
and noninvasive epithelial skin lesions
are the most frequent tumors in fair-
skinned populations. Carcinogenesis of
NMSC is related to mutations of p53
and CDKN2A (Boukamp, 2005). How-
ever, several lines of evidence support
the hypothesis that MMR deficiency
and MSI-H might have a role during
NMSC development; (1) UV light-
mediated inactivation of MMR genes
has been suspected (Young et al.,
2004), which may result in MSI-H. (2)
The immunosuppressant azathioprine is
suggested to impair the MMR system
(Karran and Attard, 2008), and thus,
MSI-H might arise and contribute to
skin cancer carcinogenesis in transplant
recipients. (3) The high incidence of
NMSC in immunosuppressed patients
suggests a central role of immunosur-
veillance as a cancer-protective mech-
anism in the skin. MSI-H cancers are
known to be particularly immunogenic
(Kloor et al., 2010), and immunosup-
pression might favor the outgrowth of
immunogenic MSI-H lesions that would
otherwise be controlled by the immune
system.
We here evaluated the MSI-H pre-
valence in a clinically well-character-
ized cohort of epithelial skin lesions
from immunosuppressed and immuno-
competent individuals using a highly
sensitive mononucleotide repeat mark-
er panel. A total of 141 epithelial skin
lesions were analyzed for MSI-H, in-
cluding 30 squamous cell carcinoma
(SCC), 53 basal cell carcinoma (BCC),
41 Bowen’s disease, 16 keratoacantho-
ma, and 1 actinic keratosis (Table 1). In
all, 79 of the lesions were obtained
from immunosuppressed renal allograft
recipients (Department of Nephrology
at the University Hospital Heidelberg,
Germany) and 62 of the lesions derived
from non-immunosuppressed patients
with regular renal function (Depart-
ment of Dermatology at the University
Hospital Heidelberg, Germany; Reus-
chenbach et al., 2011). The Ethics
Committee of the University of Heidel-
berg approved the protocol; informed
consent was obtained from patients.
The study was conducted in accor-
dance with the Declaration of Helsinki.
Paraffin-embedded, hematoxylin and
eosin-stained tissue sections were
microdissected, and DNA was extract-
ed using the DNeasy Blood and Tissue
kit (Qiagen, Hilden, Germany). PCR
with fluorescence-labeled primers was
performed to amplify the quasi-mono-
morphic mononucleotide markers
BAT25, BAT26, and CAT25 (Findeisen
et al., 2005). Fragments were visual-
ized on an ABI3100 genetic analyzer
(Applied Biosystems, Darmstadt, Ger-
many). Fragment sizes different from
the normal range of allelic size varia-
tion known for the amplicons encom-
passing BAT25 (108–110 bp), BAT26
(116–118 bp), and CAT25 (146–148 bp)
were regarded as microsatellite un-
stable (see Findeisen et al., 2005).
None of the 141 analyzed NMSCs
and noninvasive epithelial skin lesions
from immunocompetent patients and
immunosuppressed renal allograft reci-
pients displayed microsatellite insta-
bility at any of the analyzed markers
(Table 1). The complete absence of
MSI-H in our collection of non-mela-
noma skin lesions, which encompasses
the largest set of non-melanoma skin
lesions typed for microsatellite insta-
bility in transplant recipients, demon-
strates that the MSI-H phenotype is
extremely rare in epithelial tumors of
keratinized skin. This suggests that
MMR deficiency is not a relevant
tumorigenic mechanism in non-mela-
noma skin lesions, neither in immuno-
competent nor in immunosuppressed
patients.
In the literature, five studies have
analyzed the MSI-H phenotype in
NMSCs using a marker set compris-
ing more than one mononucleotide
repeat (56 SCC, including 53 from
immunosuppressed; 104 BCC, includ-
ing 7 from immunosuppressed; Saetta
et al., 2007; Mosterd et al., 2008;
Wisgerhof et al., 2009; Borie et al.,
2010; Perrett et al., 2010). MSI-H
was reported in 2 out of 160 tumors,
1 lesion with alterations in BAT25
and BAT26 and 1 lesion with altera-
tions in BAT25 and TGFBR2. Both
lesions reported as MSI-H in the
literature were BCC, and both were
Table 1. Experimental analysis of microsatellite instability of 141 epithelial skin lesions using markers BAT25,
BAT26, and CAT25
Number of analyzed lesions Microsatellite instability
Total Immunosuppressed Immunocompetent BAT25 BAT26 CAT25
Squamous cell cancer 30 13 17 0 0 0
Basal cell cancer 53 35 18 0 0 0
Bowen’s disease 41 24 17 0 0 0
Keratoacanthoma 16 6 10 0 0 0
Actinic keratosis 1 1 0 0 0 0
Total 141 79 62 0 0 0
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reported in one single study (Saetta
et al., 2007). Notably, MSI-H was
not detected in any of the analyzed
SCC lesions.
In contrast to MSI-H and mononu-
cleotide instability, instability affecting
tetranucleotides and dinucleotides, ap-
parently occurs at a higher frequency in
NMSC, but seems to be associated with
pathways of genomic instability other
than with MMR deficiency (Danaee
et al., 2002).
The results of our study conclusively
demonstrate that, in spite of anecdotal
reports of MSI-H in BCC, the MSI-H
phenotype is extremely rare in non-
melanoma skin lesions. In summary,
a relevant causative role of MMR
deficiency and MSI-H in the pathogen-
esis of epithelial skin tumors can be
excluded.
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TO THE EDITOR
We read with interest the letter by
Stockmann et al. (2011) entitled ‘‘A
wound size-dependent effect of myeloid
cell-derived vascular endothelial growth
factor on wound healing’’. The results
presented in this paper suggest that
myeloid cell-derived vascular endothelial
growth factor (VEGF) is important for
expedient closure in large excisional
wounds, where it contributes signifi-
cantly to angiogenesis and overall dermal
VEGF levels. This does not seem to be the
case in incisional wounds, where at 12
days post injury there appears to be no
significant difference in VEGF levels or
dermal scar width. Several years ago, we
demonstrated a role for VEGF in scar
formation in several models of wound
healing (Wilgus et al., 2008). We showed
that an increase in total VEGF levels
correlates with the transition from scar-
less to fibrotic healing in fetal skin and
that exposure of wounds that normally
heal in a scarless manner to exogenous
VEGF leads to scar formation. We also
showed in an incisional wound model
that antibody neutralization of VEGF
throughout the healing process signifi-
cantly reduces scar size and increases the
quality of the collagen that is deposited.
These findings are supported by multiple
other studies that link VEGF to fibrotic
reactions (Choi et al., 2003; Hamada
et al., 2005; Hakroush et al., 2009;
Karvinen et al., 2011; Lin et al., 2011).
Although our findings may seem to
contradict the study by Stockmann
et al. at first glance, several important
considerations affect the interpretation.
Our study used neutralizing antibodies,
administered repeatedly throughout the
healing process to inhibit the activity of
VEGF. This approach would neutralize
VEGF produced not only by myeloid-
derived cells, but also from other cellular
sources in the wound, including mastAbbreviations: VEGF, vascular endothelial growth factor
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